Bio-Path Holdings's book value per share for the quarter that ended in Mar. 2026 was $-0.91.
During the past 12 months, Bio-Path Holdings's average Book Value Per Share Growth Rate was -3463.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -92.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -79.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -54.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Bio-Path Holdings was 52.50% per year. The lowest was -92.80% per year. And the median was -25.40% per year.
Bio-Path Holdings's current price is $0.04. Its book value per share for the quarter that ended in Mar. 2026 was $-0.91. Hence, today's PB Ratio of Bio-Path Holdings is .
During the past 13 years, the highest P/B Ratio of Bio-Path Holdings was 13.98. The lowest was 0.01. And the median was 1.07.
Bio-Path Holdings (OTCPK:BPTH) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Bio-Path Holdings Book Value per Share Related Terms
Bio-Path Holdings Book Value per Share Historical Data
* Premium members only.
The historical data trend for Bio-Path Holdings's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPTH vs VBIO, HEPA, AXIM: Book Value per Share Comparison
For the Biotechnology subindustry, Bio-Path Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Path Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bio-Path Holdings's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Path Holdings (BPTH) has a Book Value per Share of $-0.91 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Bio-Path Holdings and its competitors.
Is Bio-Path Holdings' Book Value per Share too high?
Bio-Path Holdings' current Book Value per Share is $-0.91.
How does Bio-Path Holdings' Book Value per Share compare to VBIO and HEPA?
Bio-Path Holdings' Book Value per Share of $-0.91 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Bio-Path Holdings and its competitors. Bio-Path Holdings's current Book Value per Share is $-0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current Book Value per Share of $-0.91. The current Book Value per Share is $-0.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current Book Value per Share is $-0.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BPTH has been successfully added to your 